Toggle navigation
Home
Search
Services
Blog
Contact
About
Biology of Cytokine-Induced Killer Cells
Lu, Peggy P.
Stanford University, Stanford, CA, United States
Search 8 grants from Peggy Lu
Search grants from Stanford University
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
Modulation of colitis-associated cancer by cyclosporine A
Energy-sensing Pathways, Healthy Aging and Longevity
RNA Binding Proteins &Alternative Splicing
Function of Subunit Isoforms in Cytochrome C Oxidase
Recently added grants:
The role of Poly-ADP-Ribose Polymerase in angiogenesis of ischemic-diabetic wounds
Enrichment Program
Sox6 Role in Renin Expression During Juxtaglomerular Cells Expansion
The Identification and characterization of genetic variants underlying cardiovascular diseases
Aerosolized Nicotine Modulation of Host Inflammation and Microbiota Dysbiosis
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32CA009324-01
Application #
2085279
Study Section
Immunology, Virology, and Pathology Study Section (IVP)
Project Start
1993-04-01
Project End
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Institution
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Related projects
NIH 1994
F32 CA
Biology of Cytokine-Induced Killer Cells
Lu, Peggy P. / Stanford University
NIH 1992
F32 CA
Biology of Cytokine-Induced Killer Cells
Lu, Peggy P. / Stanford University
Publications
Lu, P H; Negrin, R S
(1994)
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
J Immunol 153:1687-96
Comments
Be the first to comment on this grant